ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX)
| Market Cap | $1.72B-19.7% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 110.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 476,197.953 |
| Open | $13.25 |
| Previous Close | $13.30 |
| Day's Range | $12.87 - $16.16 |
| 52-Week Range | $12.50 - $23.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | $33.50(+115.57%) |
| Earnings Date | n/a |
About ADRX
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.
ADARx Pharmaceuticals, Inc. Stock Analysis — InsiderScore
ADARx Pharmaceuticals, Inc. scored higher than 96% of companies evaluated by InsiderBuying, and ranked 3rd out of 90 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at ADARx Pharmaceuticals, Inc. bought $60.55 million of stock across 10 purchases in the last 90 days, the largest of them $10.07 million.
The average purchase added about 6% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
3 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades only$ADRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ADRX
| VTIVanguard Morningstar Total Stock Market ETF | $611.06K |
| VXFVanguard Extended Market ETF | $233.32K |
| VTWOVanguard Russell 2000 ETF | $79.84K |
| TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | $78.88K |
| TDNAT. Rowe Price Biotech ETF | $18.07K |
| VTWGVanguard Russell 2000 Growth ETF | $8.02K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ADRX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+4.7 since Sep 30Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.